Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Authors:
- Adithya BalasubramanianABAdithya Balasubramanian
- Claire MarceauxCMClaire Marceaux
- Sehrish KanwalSKSehrish Kanwal
- Ilariya TarasovaITIlariya Tarasova
- Daniel BateyDBDaniel Batey
- Clare SenkoCSClare Senko
- Khashayer AsadiKAKhashayer Asadi
- Kenta YokoteKYKenta Yokote
- Jodie PalmerJPJodie Palmer
- Michael ChristieMCMichael Christie
- Ashray GunjurAGAshray Gunjur
- Surein ArulanandaSASurein Arulananda
Open Access
- 14 November 2025
- other
- Published by American Association for Cancer Research (AACR)